

At page 19, line 38, please delete "lymphmokynes " and insert ---
lymphokynes---

IN THE CLAIMS

Please amend the Claims as follows:

11. (Twice Amended) A method of treating a condition or disease in a human involving tissue selected from the group consisting of underperfused tissue and pathological tissue which will benefit from the treatment by the administration of an agent selected from the group consisting of a medicinal agent and a therapeutic agent and combinations thereof, which is suitable for treating said tissue, the method [mammal] comprising administering to the human [mammal] a therapeutically effective dosage amount of a pharmaceutical composition comprising a therapeutically effective amount of the [an] agent [selected from the group consisting of a medicine and a therapeutic agent and combinations thereof] to treat the disease or condition involving tissue selected from the group consisting of underperfused tissue and pathological tissue, and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof sufficient to facilitate the transport and penetration of the agent through the tissue at a site to be treated through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person].

119. (Twice Amended) A dosage amount of a pharmaceutical composition in a suitable pharmaceutically acceptable excipient for treating a disease and condition involving underperfused tissue and pathological tissue in humans selected from the group consisting of renal failure, cardiac insufficiency, hypertension and

edema, said dosage amount comprising an effective amount of a diuretic agent for treating said disease and condition, and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof sufficient to facilitate the transport of the agent at a site to be treated by the agent [agents] passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person] and less than 1000mg.

B2
cont

184. (Twice Amended) A method of treating a disease or condition involving underperfused tissue and pathological tissue in humans selected from the group consisting of renal failure, cardiac insufficiency, hypertension and edema, the method comprising the administration of an effective amount of a diuretic agent for treating said disease or condition, and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts thereof and combinations thereof to facilitate the transport of the agent at a site to be treated by the agent [agents] passing through the tissue through the cell membranes into the individual cells to be treated, wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg[/70kg person] and less than 1000mg.

184
B3

REMARKS

Claims 11, 119-121 and 184-186 remain the Application. Some of these claims have been amended with a view of more clearly defining the invention and to overcome the grounds of rejection by the Examiner under 35 U.S.C. §112, second paragraph, without adding new subject matter.

7/12